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Abstract
The ability to assay genome-scale methylation patterns using high-throughput sequencing makes it possible to carry out
association studies to determine the relationship between epigenetic variation and phenotype. While bisulfite sequencing
can determine a methylome at high resolution, cost inhibits its use in comparative and population studies. MethylSeq,
based on sequencing of fragment ends produced by a methylation-sensitive restriction enzyme, is a method for
methyltyping (survey of methylation states) and is a site-specific and cost-effective alternative to whole-genome bisulfite
sequencing. Despite its advantages, the use of MethylSeq has been restricted by biases in MethylSeq data that complicate
the determination of methyltypes. Here we introduce a statistical method, MetMap, that produces corrected site-specific
methylation states from MethylSeq experiments and annotates unmethylated islands across the genome. MetMap
integrates genome sequence information with experimental data, in a statistically sound and cohesive Bayesian Network. It
infers the extent of methylation at individual CGs and across regions, and serves as a framework for comparative
methylation analysis within and among species. We validated MetMap’s inferences with direct bisulfite sequencing, showing
that the methylation status of sites and islands is accurately inferred. We used MetMap to analyze MethylSeq data from four
human neutrophil samples, identifying novel, highly unmethylated islands that are invisible to sequence-based annotation
strategies. The combination of MethylSeq and MetMap is a powerful and cost-effective tool for determining genome-scale
methyltypes suitable for comparative and association studies.
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Introduction
New methods that assay epigenetic modifications over the whole
genome promise to reveal insights into cell differentiation and
development [1–15]. Moreover, incorporation of genome-scale
epigenetic data into case-control studies is now becoming feasible,
and has the potential to be a powerful tool in the study of disease
[16]. Recent evidence has suggested that epigenetic variation is
heritable, and may underlie phenotypic variation in humans ([17],
our own observation with the human and chimpanzee methy-
lomes). Such comparative studies rely both on the ability to obtain
genome-scale epigenomic information cheaply and efficiently, and
on the availability of methods for analysis of the data produced.
Cytosine methylation, which in vertebrates is mostly confined to
CG dinucleotides, cooperates with other epigenetic modifications
to suppress transcription initiation [3,18] (in this paper we denote
a cytosine that is followed by a guanine as CG, rather than CpG,
and similarly CCGG is equivalent to CpCpGpG. We leave the
notation for CpG islands unchanged). In vertebrates, most CGs
are methylated. However, early experiments with the methylation-
sensitive restriction enzyme HpaII showed that unmethylated CGs
are clustered in ‘‘HpaII Tiny Fragment Islands’’ [19]. These
unmethylated islands are frequently active promoter elements.
Methods used to annotate them on a genomic scale have been
based only on sequence composition, because until recently
genome-scale assessment of HpaII fragments has not been
practicable. The methylation status of these regions, known as
CpG islands, has not been considered in their annotation and is
generally unknown. Genome-scale survey of the methylation status
of CGs would enable the annotation of CpG islands based on their
methylation states, rather than their sequence. Patterns of
unmethylated islands differ among tissues, and changes in the
methylation states of certain regions are associated with disease,
particularly cancer [2,3,20–22].
High-throughput sequencing technologies have catalyzed the
development of new methods for measuring DNA methylation.
These methods can be broadly classified as methyltyping versus
methylome sequencing, in analogy with genotyping versus genome sequencing
for DNA. Methyltyping technologies allow for the assessment of
genome-scale methylation patterns, while emphasizing low cost at
the expense of high resolution. Assays based on sequencing avoid
problems associated with hybridization to arrays. Examples
include MethylSeq, which is based on digestion with a
methylation-sensitive enzyme and is the focus of this paper, and
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enzyme followed by bisulfite sequencing [3,23]. In contrast to
methyltyping, whole-genome bisulfite sequencing offers the ability
to measure absolute levels of DNA methylation at single-
nucleotide resolution [7,24,25], but it is expensive because it
requires sequencing of whole genomes. The issues of cost and
coverage are complicated by a number of other issues. In the case
of bisulfite sequencing, conversion may not always be complete.
Also, the analysis requirements for the different assays vary in
difficulty. For these reasons, there has been a proliferation of
methods whose pros and cons are constantly changing as
sequencing technologies change. A recent analysis (Table 2 in
[26]) suggested that MethylSeq is the method with the most
favorable profile of pros and cons, with respect to the measures
chosen for comparison. Table 1 summarizes characteristics of
MethylSeq and of the most commonly used alternative methods.
MethylSeq retrieves information spanning more of the genome
than RRBS, because of a more favorable profile of fragment sizes
produced by HpaII relative to MspI (see the discussion of size
selection bias below and the Methods section).
MethylSeq is a convenient methyltyping strategy because it is
cost-effective, requires only small amounts of material, and avoids
bisulfite conversion. Briefly, the assay works by digestion of DNA
with a methylation-sensitive enzyme (HpaII) that cuts unmethy-
lated CGs at CCGG sites. Subsequent sequencing and mapping to
the genome reveals unmethylated CGs (Figure 1). Although the
experiment is relatively simple, interpretation of the sequencing
data is confounded by the dependence of read depth at a given site
on the methylation status of neighboring sites. This has limited the
use of MethylSeq; previous studies either pointed out the need for
a method of site-specific normalization [1], or attempted to deal
with the bias by removing problematic HpaII sites from the
analysis [5](resulting in the loss from the analysis of more than
19% of HpaII sites in CpG islands, see Methods).
In order to make effective use of MethylSeq for genome-scale
methyltyping we developed a freely available program, called
MetMap, that infers methylation at individual CGs by modeling
biases inherent in MethylSeq experiments. An additional impor-
tant feature of MetMap is the annotation of strongly unmethylated
islands (SUMIs) which, as opposed to the current definition of
CpG islands, incorporate information from both a reference
sequence and genome-scale methylation data. We have validated
MetMap’s site-specific analysis, as well as its unmethylated-island
annotation, with bisulfite sequencing of specific sites.
We demonstrate the use of MethylSeq with MetMap by
methyltyping four male human individuals, and annotating their
unmethylated islands. We show that the picture revealed by such
analysis is sufficient to survey methylation states across the
genome. Such analysis gives significant insight into the methylome
of each specimen, inside and outside of CpG islands, at site specific
resolution. We show evidence that the mean extent of methylation
of an island is more informative than the methylation state of the
different sites in the island, because the correlation between the
methylation states of any two samples improved when considering
the mean. MetMap identifies numerous unmethylated regions, of
varying lengths, which have not previously been annotated as
CpG islands and are associated with other features indicative of
transcriptional function. We conclude that MetMap leverages the
cost-efficiency and practical ease of MethylSeq to produce
informative genome-scale methylation annotations (methyltypes)
that are suitable for both region- and site-specific comparative and
case-control studies.
Author Summary
In the vertebrates, methylation of cytosine residues in DNA
regulates gene activity in concert with proteins that
associate with DNA. Large-scale genomewide comparative
studies that seek to link specific methylation patterns to
disease will require hundreds or thousands of samples, and
thus economical methods that assay genomewide meth-
ylation. One such method is MethylSeq, which samples
cytosine methylation at site-specific resolution by high-
throughput sequencing of the ends of DNA fragments
generated by methylation-sensitive restriction enzymes.
MethylSeq’s low cost and simplicity of implementation
enable its use in large-scale comparative studies, but
biases inherent to the method inhibit interpretation of the
data it produces. Here we present MetMap, a statistical
framework that first accounts for the biases in MethylSeq
data and then generates an analysis of the data that is
suitable for use in comparative studies. We show that
MethylSeq and MetMap can be used together to
determine methylation profiles across the genome, and
to identify novel unmethylated regions that are likely to be
involved in gene regulation. The ability to conduct
comparative studies of sufficient scale at a reasonable
cost promises to reveal new insights into the relationship
between cytosine methylation and phenotype.
Table 1. Features of different methyltyping techniques.
Site
specific
Pre-chosen
regions
Spanning
of human
genome
Spanning
of CpG
islands #CG sites
Bisulfite
conversion Read length
Constraints on
analysis
Comparable with
low amounts of
input DNA
MethylSeq Yes No 9.2% 92.9% *1:4M Not Needed 32bp suffice Inference Procedure
Needed
Yes
RRBS Yes No 8.1% 69.8% *1:4M Needed Longer=more
coverage
Low Sequence
Complexity
Yes
Affinity-based (MeDIP,
mDIP, mCIP)-Seq
No No whole
genome
all - Not Needed 32bp suffice Binding Biases No
Affinity-based (MeDIP,
mDIP, mCIP)-Array
No Yes pre-chosen pre-chosen - Not Needed - Binding Biases+Array
Biases
No
For definition of spanning and determination of number of sites, see Methods. Constraints on analysis: for MethylSeq, see this paper. For RRBS, bisulphite conversion
lowers sequence complexity, complicating alignments. Affinity based methods are complicated by effects of methylation density on binding, and by noise created by
non-specific binding. Array methods are complicated by noise in the hybridization step. This table makes use of information from Laird 2010 [26].
doi:10.1371/journal.pcbi.1000888.t001
MetMap Enables Genome-Scale Methyltyping
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by explaining in detail significant biases present in MethylSeq
experiments. We then describe the MetMap framework, which is
designed to correct for such biases, starting with a description of
MetMap’s graphical model and continuing with a description of
the software’s different outputs. We then describe the validation of
MetMap’s procedure, using the methyltypes of four human
individuals, and our discovery of new unmethylated regions in
the human neutrophil genome, found through the use of MetMap
on MethylSeq data. Finally, we discuss the advantages of using
MetMap with MethylSeq to generate and analyze large numbers
of samples, and outline our plans for the extension of MetMap’s
framework.
Results
Computational Model
Rationale. MetMap is a statistical inference framework that
exploits MethylSeq data to accurately ascertain the extent of
methylation across a genome. It uses a novel graphical model to
assign probabilities of methylation at single-HpaII-site resolution,
annotate regions of the genome that are hypomethylated along
with a score indicating their extent of hypomethylation, and
indicate the sites that are in the scope of the MethylSeq
experiment and may be included in comparative studies.
A central feature of MetMap is its ability to normalize the bias
introduced in short-read sequencing experiments in which the
genome is not randomly fragmented. In MethylSeq experiments, all
unmethylated HpaII sites are present at the ends of the digested
fragments, but a size selection step required by the sequencing
protocol limits sequencing to fragments of a narrow size range. The
methylation status of the neighbors of an unmethylated HpaII site
determines whether the fragments with this site at their ends will
pass the sizeselection step and be sequenced(Figure 2.a). Moreover,
the methylation state of CG sites can be heterogeneous even within
a population of a single cell type [5,14]. This complicates correction
for the bias introduced by size selection (Figure 2.b). MetMap
incorporates experimental data derived from a site’s ‘‘neighborhood
methylation structure’’ to achieve unbiased estimates of the
probability of methylation, at single-site resolution.
Another bias is an issue of all ‘‘shotgun’’ sequencing
experiments. The read count of a given fragment gives only an
estimate of its abundance in the solution, and can be viewed as the
number of times the fragment was randomly sampled. Therefore,
different fragments present in the specimen in similar quantities
will not always be sequenced to the same extent. The site-specific
inference procedure used by MetMap considers the extent to
which all fragments in a HpaII site’s neighborhood were
sequenced, so that more information is considered to determine
the state of each HpaII site.
MetMap’s graphical model. The analysis of a MethylSeq
experiment by MetMap begins with the generation of a directed
graphical model. The model’s specific structure is determined by a
reference genome and the specifications of the given experiment.
We outline the different types of variables in MetMap’s model, the
dependencies between the variables, and how the data is
incorporated into the ‘‘observed’’ states.
For a given reference genome, MetMap denotes every CG that
is within a HpaII site (CCGG) by a random variable (denoted by
Ys, large open circles in Figure 3.b), and every non-HpaII CG by
Figure 1. Determination of genome-scale methylation states with MethylSeq/MetMap. Genomic DNA is digested with the methylation-
sensitive restriction enzyme HpaII. Unmethylated HpaII sites (open circles) are digested and thus found at the ends of restriction fragments, while
methylated HpaII sites (black circles) are not digested. Restriction fragments are size-selected according to the Illumina protocol; fragments that are
either too long or too short are removed. Fragments that pass the size-selection are used to construct sequencing libraries. After sequencing, the raw
reads are aligned against the reference genome and processed with MetMap to derive maps of genome-scale methylation.
doi:10.1371/journal.pcbi.1000888.g001
Table 2. Counts of the SUMIs annotated in the four human neutrophil samples.
All Neutrophil
SUMIs Overlapping CGIs
Not Overlapping
CGIs Overlapping BFIs
Not Overlapping
BFIs
Not Overlapping
CGIs or BFIs
Sample 1 16,903 14,071 2,832 12,076 4,827 2,266
Sample 2 17,595 15,008 2,587 12,834 4,761 2,044
Sample 3 18,178 15,273 2,905 13,082 5,096 2,308
Sample 4 18,699 15,274 3,425 13,229 5,470 2,729
Union 20,985 16,334 4,651 13,931 7,054 3,797
Intersection 14,308 12,838 1,470 11,123 3,185 1,116
Union - The set of regions annotated as a SUMI in at least one of the four individuals. Intersection - The set of regions annotated as a SUMI in all four individuals. CGIs -
UCSC CpG islands. BFIs - BF-islands.
doi:10.1371/journal.pcbi.1000888.t002
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Figure 3.b). Each HpaII site variable takes on one of six states.
Each state incorporates one of the three values fM, U, Pg
determining the site as methylated, unmethylated and heteroge-
neously methylated respectively, and one of the two values fI, Ng
determining the site’s presence (or not) in an unmethylated island.
Each non-HpaII-site CG variable (Z) has two possible states:
fI, Ng. Z variables do not incorporate methylation values
because there is no experimental data on non-HpaII CG sites.
Every genomic fragment that could be produced by cleavage of
any two HpaII sites, and which passes the size selection step, has a
corresponding random variable (denoted by Vs, blue circles in
Figure 3.b). In other words, these are all possible fragments in the
given size range that have a HpaII site at each end. The V
variables are the observed variables of the model. Each V variable
has a state determining the relative extent (0 being the lowest and
9 the highest) to which the specific fragment it represents was
detected by MethylSeq. V variables range over 0–9 to account for
heterogeneous methylation of sites within a population of cells
[5,7] and are assigned by a normalization procedure that is
applied to the read counts (Methods). In summary, the variables of
the model have the following possible states:
Yi [ fMI, PI, UI, MN, PN, UNg,
Zi [ fI, Ng,
Vi [ f0, 1, ...,9 g:
Dependencies between the variables are modeled using
probability distributions of three types, making use of 54
parameters. The first type of probability distribution captures
the dependencies between adjacent CG sites with respect to
whether the sites are part of an unmethylated island, and is
modeled by transition probabilities of a hidden Markov model
(HMM) that incorporates the distances between adjacent sites.
The second determines, for each Yi, its probability of being in
each of the three methylation values described above, given
placement of the site in an unmethylated island (or not). The third
type models the generation of MethylSeq experimental results, and
thus the bias present in such experiments: the presence of a
fragment (a V variable) in the data requires that it was cut at its
ends, and not between them. MetMap incorporates values for
p(vDConf), where v denotes a state of V, and Conf is some
methylation value configuration of the Y variables (ends and
interior) on the fragment V represents. Further details about the
transition functions are found in the Methods section.
In summary, the reference genome specifies the structure of the
graphical model, and the MethylSeq data is incorporated into this
model by fixing the states of all of the V variables (Figure 3.a,b).
This integrates into one inference model our knowledge of the
MethylSeq data, of the main sources of experimental bias, and of
the genome sequence.
Site-specific methylation probabilities. After building the
probabilistic model and assigning the V variables, MetMap infers,
for each of the ‘‘hidden’’ Y and Z variables, the posterior
probability over its states (Figure 3.c). To do this MetMap uses
belief propagation on the junction-tree graph built from the
directed model [27]. The computation is tractable and efficient
because the tree width of the model is small (Methods). Given the
posterior probabilities, the probability of each restriction site, Yi,
to be unmethylated or methylated is respectively:
pi(U)~pi(UI)zpi(UN)z
1
2
(pi(PI)zpi(PN))
pi(M)~pi(MI)zpi(MN)z
1
2
(pi(PI)zpi(PN)):
It is important to restrict analysis only to sites that are within the
scope of the MethylSeq experiment, namely, to sites for which the
MethylSeq experiment holds some information regarding their
methylation state. MetMap identifies these sites from the structure
of the graphical model (Methods) and outputs a file with
coordinates of all CCGG sites in the scope of the experiment,
along with their inferred p(U) values.
Strongly unmethylated islands (SUMIs). As unmethylated
CGs tend to be clustered in vertebrate genomes, we would like to
annotate the coordinates of these clusters. We call such regions
SUMIs (strongly unmethylated islands) and emphasize that they are
defined by experimental data and so are specific to a dataset. In
MetMap’s graphical model the posterior probability of a variable to
be in an ‘‘unmethylated island’’ state is dependent on both the
genome sequence and the experimental data (for any Yi variable
Figure 2. The methylation state of restriction site B cannot be
determined by its read count alone. Suppose that due to the size
selection step, only fragments of length 50–300bp are sequenced. The
four adjacent restriction sites (denoted by circles) may have different
methylation states, resulting in epialleles with different ‘‘neighborhood
methylation structures’’ of B. Site B is sequenced only from fragments of
type B–C–D, which are the product of alleles in which sites B and D are
unmethylated (and cut) and site C is methylated (and not cut). (a)Bi s
unmethylated in both case 1 and case 2, but it receives different read
count values. In case 1 sites A,B and D are unmethylated and therefore
digested by HpaII, giving fragments A–B of length 10bp and B–C–D of
length 100bp. Fragment A–B is too short to be sequenced, but B–C–D
has its ends sequenced. In case 2 all four HpaII sites are digested, giving
fragments A–B, B–C and C–D. A–B and B–C are too short and are not
sequenced, and so site B is not sequenced. In case 3, site B is
methylated, is not cut by HpaII, and is not sequenced. Note that the
read counts at site B alone cannot distinguish case 2 from case 3. (b)
Analysis is complicated by heterogeneous methylation within a
population of cells. The extent to which site B is methylated in the
cell population cannot be determined given only the read count at site
B. In case 4, although site B is cut in 90% of the cells, it is sequenced
only infrequently, because site C is unmethylated and cut in 90% of the
cells, resulting in a B–C fragment that is too short for sequencing. In
contrast, in case 5 site B is cut in only 10% of the cells. But site C is
methylated in 90% of cells, so the majority of the fragments in which
site B has been cut will yield a B–C–D fragment and will be sequenced.
Thus the methylation structure of neighboring restriction sites strongly
influences the frequency with which a site will be sequenced.
doi:10.1371/journal.pcbi.1000888.g002
MetMap Enables Genome-Scale Methyltyping
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could cause sites with a very high concentration of CGs around
them to get high posterior probabilities of being in the
‘‘unmethylated island’’ state, regardless of experimental data at
those regions. MetMap accounts for this by annotating SUMI
regions based on several different properties: the inferred
probabilities of being in an unmethylated island, of being
unmethylated and the direct MethylSeq data (Methods). Each
SUMI receives a score indicating the extent to which the entire
SUMI is unmethylated. This score is the mean of the p(U) scores of
all of the HpaII sites within that SUMI. SUMIs can be used as
‘‘comparative units’’, facilitating the comparison of datasets.
MetMap outputs a file with the coordinates and scores of the
SUMIs inferred for a dataset.
Evaluating MetMap’s Performance
Wecarried outMethylSeqonspecimensofa single homogeneous
and uncultured cell type, the neutrophil, from four male humans.
HpaII fragments were size selected in the range 50–300bp and
sequenced on a first generation Illumina Genome Analyzer yielding
23,731,359 32bp reads. Although longer reads are currently
available, reads for our assay only need to be sufficiently long so
that they can be mapped correctly to the reference genome. The
reads were aligned to the reference human genome (hg18 [28]) with
Bowtie[29] resultingin18,218,420 alignments (Table S1), and each
of the four samples was analyzed with MetMap.
To infer methylation states from read depths, we first segmented
the genome into 6,000 non-overlapping regions (of size 0.5Mbp)
that could be analyzed separately. For each region, MetMap
returned methylation probabilities for those CCGG sites for which
information on site-specific methylation could be obtained from
the MethylSeq experiment, and annotated SUMIs. The CCGG
subset contained 59% of the CCGG sites (4.8% of all CG sites) in
the human genome. Of the sites for which information could be
obtained, 80% (1,035,243 sites) were outside CpG islands as
annotated in the UCSC Genome Browser [30], and 20% (257,540
sites) were inside, resulting in a two-fold enrichment of the
proportion of CCGG sites that are in such CpG islands.
Figure 3. Inference of site-specific probabilities of unmethylation and annotation of strongly unmethylated islands from
MethylSeq read counts. MetMap constructs a directed graphical model (b) from the genome and read counts (a). The methylation state of each
CCGG site is represented by a random variable that also encodes whether it is in an unmethylated island. CpG sites are also represented in the model,
with the distance between sites affecting the parameters. The read counts are used to set the state of the observed random variables corresponding
to the possible sequenced fragments (for simplicity of representation, only a sample of these variables is outlined in the figure). The numbers in the
blue circles represent normalized read counts. Dark edges correspond to boundaries of fragments. MetMap inferences of the extent of unmethylation
(c) are shown alongside the values attained from a bisulfite sequencing validation. The raw read counts are scaled by the cmax value chosen for
sample 4 (Methods). Strongly Unmethylated Islands are annotated from the posterior distributions inferred at sites and the total read counts. The
example shows part of an inferred SUMI on chromosome 19 from sample 4.
doi:10.1371/journal.pcbi.1000888.g003
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(Figure 3), we directly determined the methylation status of 22
regions in the human genome using bisulfite sequencing [31]
(Methods). Each CG in the bisulfite experiment received a score
from the set (0,0.25,0.5,0.75,1) based on the observed proportion
of alleles in which that site was unmethylated in a sample [32].
We correlated the bisulfite scores (taken as being the true
methylation status) with the read counts and with the MetMap
predictions. Each of the 46 validated sites had three different
scores for the extent to which it was unmethylated: a bisulfite
score, a read count score, and a MetMap score. The Pearson
correlation coefficient between the raw read counts and the
bisulfite values was 0.67 while the Pearson correlation coefficient
between the MetMap methylation score of those sites and the
bisulfite values was improved to 0.90.
As the bisulfite scores may be an imprecise measure of the true
extent of methylation (Methods) we tested the sensitivity of our
results to the bisulfite scores. We ‘‘adjusted’’ bisulfite scores,
assigning to each value of the two sets of scores, the read-count set
and the MetMap predictions set, a separate ‘‘adjusted’’ bisulfite
value, that is within a predetermined range. The range available
for adjustment was determined by the initial bisulfite score
(Methods). After this adjustment, the correlation coefficient of the
read counts with the bisulfite scores was 0.73 and the correlation
coefficient of the MetMap scores with the bisulfite scores was 0.95.
While the correlation values increased as expected, the difference
between the performance of MetMap and that of read counts
remains similar. This indicates that the improvement in using
MetMap instead of raw read counts was not due to the procedure
by which bisulfite scores were assigned.
Examples of MetMap’s ability to accurately detect partially and
fully methylated sites are shown in Figure 3, Figure S1 and Text
S2. Both the extent and variability of methylation in a region are
better predicted by MetMap than by the read counts.
To determine which parameter might be more informative for
genome-scale methyltyping, we compared methylation states for
individual sites and for SUMIs between pairs of samples. Although
themethylationstatusofindividualsiteswithinSUMIswasvariable,
the average probability of methylation for the whole SUMI was
consistent across individuals (Figure 4). This observation suggests
thatthemeanmethylationstate ofa SUMI ismoreconstrained than
the methylation states of the individual sites within it, and thus a
change in mean SUMI methylation is more likely to havefunctional
consequences than a change at a specific site. Based on this, we
propose that the mean SUMI methylation status is the more
informative parameter for comparative or association studies.
Similar read counts at orthologous restriction sites in two or
more samples indicate that their methylation status is similar;
however determination of their true extent of methylation requires
a statistical method such as MetMap. Thus the degree of
consistency observed among MetMap’s site-specific inferences
for different samples is supported by the high correlation of the
corresponding raw read counts (e.g.: a correlation of 0.667
between sample 1 and sample 4).
Figure 4. The average probability of methylation at SUMIs is highly stable across individuals of the same sex. All pairings among the
four individuals tested are shown. On the left side of each pair the correlations between the site specific MetMap scores are presented for sites within
SUMIs. On the right side of each pairing the correlations of the SUMI scores are presented. The distribution of the sites that are highly unmethylated
in one sample but methylated to different extents in the other sample is discussed in Text S3.
doi:10.1371/journal.pcbi.1000888.g004
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Associated with Promoters and Open Chromatin Regions
We mapped the 20,986 SUMIs present in at least one of the
four individuals, and examined their relationship to purely
sequence based definitions of CpG islands (Figure 5.a). Of the
20,986 SUMIs present in at least one of the four individuals, 4,652
do not overlap UCSC CpG islands, and 7,055 do not overlap the
‘‘bona fide’’ islands [33] with an epigenetic score larger than 0.5
(as recommended by Bock et al. [33], termed here BF islands).
This result is consistent with the higher specificity, but lower
sensitivity, of BF compared to UCSC island prediction. Details
regarding the extent of overlap between SUMIs and the BF and
UCSC islands can be seen in Table 2.
We compared the length distribution of our SUMIs with the
length distributions of both the UCSC and BF islands (Figure 5.b).
SUMIs were similar to BF islands, but the length distribution of
the UCSC CpG islands resembled a geometric distribution. The
process by which UCSC CpG islands are annotated will produce
false positives that follow a geometric length distribution, with the
number of false positive CpG islands increasing as a function of
decreasing length (Methods). Since the length distributions of
SUMIs and BF islands do not follow the same trend as the UCSC
CpG island distribution, it is probable that at the shorter lengths
the majority of predicted UCSC CpG islands are false positives.
SUMIs did not overlap completely with BF islands: of the 21,626
BF islands, 13,899 were identified as SUMIs. BF islands are
determined with a support vector machine that uses epigenetic
data from multiple sources to train its prediction model. In
contrast, MetMap’s SUMI predictions originate from an exper-
imental signal for unmethylation in the cell type analyzed. The
probable explanation for the MetMap/BF discrepancy is that the
two methods have used epigenetic data from different tissues.
More data from distinct cell types will shed light on this issue.
We therefore validated with direct bisulfite sequencing five
regions that are annotated as part of both a UCSC CpG island
a n daB Fi s l a n d ,a n dd i dn o to v e r l a pw i t hS U M I s ;w ea l s o
sequenced three regions in BF islands that did not overlap with
SUMIs or with UCSC CpG islands. In all cases those regions
were validated as methylated in the neutrophil samples (Figure
S1.j–q). This is consistent with the notion that while these
islands might be unmethylated in other cell types, they are
methylated in the neutrophil. We analyzed four cases of
SUMIs with scores higher than 0.5 that overlapped UCSC
CpG islands but not BF islands (Figure S1.a–d). In each SUMI
a region was picked and bisulfite sequenced. All four regions
were determined as fully unmethylated (all CG sites received a
score of 1).
3,797 SUMIs do not overlap with BF islands or CpG islands,
revealing new regions that are unmethylated in neutrophil cells. Of
these novel SUMIs, 2,317 (61%) are within regions experimentally
determined by the ENCODE project as open chromatin
(Methods), 1,882 (50%) are within regions determined as
conserved by the 17-way UCSC conservation track, 2,274 (60%)
are within 2Kbp of RefSeq genes, and 837 (22%) are within 2Kbp
of the 59 end these genes (Figure. 5.c and Table 3).
Consistently with their similarity to conventional CpG islands,
SUMIs are enriched near the transcription start sites (TSSs) of
RefSeq genes, with a preference for the downstream side
Figure 5. Strongly Unmethylated Islands (SUMIs) in the neutrophil methylome. Genomewide SUMI predictions (a) reveal strongly
unmethylated islands that are proximal to genes and that do not always correspond to sequence-based annotations of CpG islands shown in the
tracks ‘BF islands’ and ‘CpG islands’ (e.g., the promoter of LRG1 and in an intron of SH3GL1). (b) SUMI and BF island length distributions have a
different shape than the CpG island length distribution, suggesting numerous short false positives in the latter. (c). Some SUMIs appear 59 of
alternative promoter sites.
doi:10.1371/journal.pcbi.1000888.g005
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novel SUMIs alone (Figure 6.b), or when we consider only SUMIs
that do not overlap UCSC CpG islands (Figure 6.c) or BF-islands
(Fig. 6.d). This indicates that the distribution of novel SUMIs
around the TSSs does not originate from a characteristic present
in only one of these sets. We find that the proportion of SUMIs
that maps at a distance from TSSs is larger for novel SUMIs than
for all SUMIs, but that novel SUMIs have a degree of association
with open chromatin similar to that observed for all SUMIs
(Table 3); this suggests that novel SUMIs may often represent
distal regulatory sequences.
Discussion
The possibilities and potential of DNA methylation analysis
with new sequencing technologies have been described as a
‘‘revolution’’ [26]. The vast number of methods for methylation
analysis, along with many papers describing exciting findings,
suggests that this revolution is underway. For the foreseeable
future, methods that rely on the construction of a sequencing
library produced by methyl-sensitive enzymes, followed by
sequencing to measure methylation, are the practical approach
for the analysis of large numbers of samples [26]. The efficient use
of MethylSeq data requires a computational method that can infer
true methylation states by considering biases inherent in the
technical method. We have developed MetMap, which makes it
possible to use MethylSeq for genome-scale methyltyping.
MetMap facilitates the rapid calling of restriction-site-specific
methylation, and of unmethylated regions, to produce methylation
maps that are suitable for comparative analysis. Validation of
MetMap calls with bisulfite sequencing shows that it compensates
for bias present in the MethylSeq data. MetMap can combine
experimental data and genome sequence to identify many strongly
unmethylated islands (SUMIs) that were previously unannotated,
suggesting that it can identify novel functional regions.
The annotation of experiment-specific strongly unmethylated
islands (SUMIs) reconciles the original definition of CpG islands,
based on their sensitivity to methylation-sensitive restriction
enzymes [19] with the sequence-based definitions now used. The
definition of SUMIs is functionally more exhaustive than the
standard definition of CpG islands, since it couples sequence clues
to methylation (abundance of CpGs) with experimental measure-
ments of methylation. In our comparison of four humans, we
noted that the average methylation states of SUMIs were more
conserved among individuals than the methylation states of sites
within them, suggesting that average methylation is more likely to
be functionally important and so is a more informative parameter.
SUMIs lie proximal to genes (77% are within 2Kbp of genes; 60%
are within 2Kbp of the 59 end), and are likely to be directly
involved in regulation of gene expression.
Overall, we predicted 3,797 SUMIs that do not overlap UCSC
CpG islands or BF islands. Their sequence conservation and
c o r r e l a t i o nw i t ho p e nc h r o m a t i ns u g g e s t st h a tt h e ya r ef u n c t i o n a l ,
but they are less frequently associated with transcription start sites
than the general set of SUMIs. Wespeculate that many novel SUMIs
are enhancers. The discovery of these novel regions illustrates the
utility of using experimental data to annotate CpG islands.
As more methylation data becomes available, the MetMap
program we have developed can be refined and improved. For
example, with the advent of methylation-based case-control
studies, it should be possible to define methyl-haplotypes and to
leverage MetMap to explore variation within and between
individuals. MetMap’s graphical model can also be used to learn
the dependencies between the methylation states of neighboring
CG sites, which will expand the scope of MethylSeq experiments
to include sites that are not directly assayed. As more data-types
Table 3. Percentages of neutrophil SUMIs, UCSC CpG islands and BF-islands that overlap regions associated with functionality.
Human Neutrophil
SUMIs UCSC CpG islands BF islands Novel SUMIs
Open Chromatin 70.0% 52.9% 65.3% 61.0%
UCSC 17-way Conservation Track 71.1% 68.5% 76.2% 49.6%
Gene Regions 76.9% 77.7% 79.7% 59.9%
TSS Regions 59.8% 52.2% 61.4% 22.0%
‘‘Open Chromatin’’ - the union of the regions determined by the ENCODE project as open chromatin in five different cell types (Methods). For the gene regions and TSS
regions the RefSeq genes were used, and a window of 2Kbp was taken around each gene/TSS.
doi:10.1371/journal.pcbi.1000888.t003
Figure 6. Transcription start sites and their close surroundings are enriched with novel SUMIs. The number of SUMIs that overlap each
location within 5Kbp from RefSeq transcription start sites is shown for (a) all neutrophil SUMIs (b) Novel SUMIs (SUMIs that do not overlap UCSC CpG
islands or BF islands) (c) SUMIs that do not overlap BF islands (d) SUMIs that do not overlap UCSC CpG islands.
doi:10.1371/journal.pcbi.1000888.g006
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expanding MetMap to include information from related genomes,
and possibly other related measurements. Ultimately, we look
forward to the coupling of methylation data with other functional
information, including expression measurements and chromatin
structure assays, to fully reveal the roles and consequence of DNA
methylation.
Methods
Ethics Statement
Human samples were collected with CHORI’s IRB approval
after obtaining informed consent.
Software
The MetMap software takes as input: (1) the mapped reads of a
MethylSeq experiment, (2) the boundaries on the lengths of the
fragments sequenced (determined by the size-selection step), and
(3) a reference genome. It outputs two files: (1) a list of the HpaII
sites in the scope of the experiment with their MetMap scores, and
(2) a list of SUMI regions with their scores.
MetMap is free, open source software, and can be downloaded
from the following site:
http://www.cs.berkeley.edu/meromit/MetMap.html
Evaluating Per-Site Coverage and Span of Methods for
Methyltyping
In the Methylseq experiment, information regarding the
methylation state of a CCGG site can be obtained for the subset
of CCGGs that are present on some fragment that has CCGG
sites at its ends and that passes the size selection step (see ‘‘CG sites
in the scope of the MethylSeq experiment’’ section for details). We
computed the number of CCGGs of the human genome that fulfill
this criterion to be 1,349,378.
In the RRBS protocol the genome is digested with the
methylation-insensitive restriction enzyme MSPI (which cuts at
CCGG sites), and the fragments of size 40–220bp are size-selected
and have their ends sequenced (after bisulfite treatment). For the
human genome RRBS determines the methylation status of
*1:4M CGs [23].
We determine the span of a methyltyping method by considering
regions in which that method profiles methylation. By doing so we
gain an insight to the broadness of a method with respect to the
regions forwhich it profilesmethylation.In MethylSeq, methylation
status is determined for a subset of the CCGG sites and in RRBS
methylation status is determined for CG sites that are within
fragments that have CCGG sites on both ends and which are of
relative short length (up to 220bp). We therefore computationally
categorized all CCGG sites of the human genome as 1/0 based on
the ability to infer their methylation state with each method. All
regions (bounded by CCGG sites) in which all CCGG sites received
a ‘‘1’’ were considered as spanned by the method. When
determining the span for CpG islands, the regions spanned were
computed in the same manner, but considered only regions within
CpG islands. In cases that the CCGG nearest to an edge of the
island was determined as ‘‘1’’ the region between that CCGG and
the edge of the island was also considered as spanned.
Coverage of Ball MP et al. (Nat Biotech 27:361–368
(2009))
In the protocol used for this study the genome is digested with
the methylation-sensitive restriction enzyme HpaII and only
CCGG sites that follow certain criteria (as outlined in Ball MP
et al.) are considered for their methylation status. One of the
requirements is that the CCGG site be at least 40bp away from at
least one of its two neighboring CCGG sites. In the human
genome 19% of the CCGG sites have both of their neighboring
CCGG sites at a distance smaller than 40bp, and are therefore
excluded from the analysis.
Characterization of False-Positive UCSC CpG Islands
CpG islands in the UCSC track are defined in [34] as regions
with a GC content of 50% or more, a length greater than 200bp,
and a greater than 0.6 ratio of observed CG dinucleotides to the
expected number based on the GC content of the segment. The
segments to consider are collected by scoring all dinucleotides (+17
for CG and 21 for others) and identifying maximally scoring
segments. Under this model, the probability that a region from the
null model (sequence which is not an unmethylted region) fulfills
these requirements increases as the length of the region decreases.
This statement holds for models in which the probability of
observing an A/T in the null model is larger than that of observing
a C/G. This is indeed the case in humans. The likelihood of false
positives in the UCSC CpG island set has been noted [33,35].
MethylSeq Experiment
We obtained whole blood from four young adult male humans
and obtained neutrophils by first isolating peripheral blood
mononuclear cells by Ficoll separation, then purifying neutrophils
with anti-CD16 antibodies conjugated to magnetic beads
(Miltenyi); we verified that the purified samples contain w99%
neutrophils by Wright-Giemsa staining and visual inspection by a
hematologist. Genomic DNA was isolated using the DNeasy Blood
& Tissue isolation kit (Qiagen), quantified using a Nanodrop
spectrophotometer, and quality-controlled for purity with an
Agilent Bioanalyzer. Genomic DNA (2mg) was digested with HpaII
under conditions that make it very likely that digestion is complete
(overnight with enzyme boosting), fragments 50–300bp long were
isolated from an agarose gel, and single-read sequencing libraries
were prepared following the manufacturer’s protocol (Illumina).
Libraries were sequenced on a first-generation Illumina Genome
Analyzer and 32 base reads were generated. Only reads beginning
with ‘‘CGG’’ (the sequence of the ends produced by restriction
with HpaII) were retained and analyzed with MetMap.
MetMap’s Algorithm
MetMap receives as input the output of the MethylSeq
experiment mapped to a reference genome, the reference genome,
and the minimal and maximal lengths of the fragments sequenced,
denoted by lmin and lmax. MetMap generates its graphical model
(the Y, Z and V variables along with their dependency relations)
from the reference genome and the values of lmin and lmax. Having
the graphical model’s structure in place, MetMap incorporates the
MethylSeq data by assigning values to all V variables (all fragments
that may be sequenced in the MethylSeq experiment): each V
variable is assigned a score between 0 and 9, by fixing a dataset-
specific ‘‘capping’’ value, denoted cmax (see next section), and to
each Vi, with paired-end read count ci, assigning
h(ci)~q
min(ci,cmax)
cmax
:9r. In case of a single-end dataset a
transformation approximates a paired-end dataset, and the data is
scaled as if it were paired-end (Text S1). MetMap is modular,
allowing for potential incorporation of methods that normalize for
biases generally present in short-read sequencing technologies [36].
Several types of probability distributions annotate the dependen-
cies between the variables of MetMap’s model. The transition
probabilities between each pair of adjacent variables of type Y and/
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genome but not the MethylSeq data, and are the prior distribution
over the hidden states. In case that the two adjacent variables are of
type Z,they takeona state (denoted byz)fromfI,Ng. Thetransition
probabilities are p(zi~IDzi{1~I,di), p(zi~NDzi{1~I,di),
p(zi~IDzi{1~N,di) and p(zi~NDzi{1~N,di),w h e r edi is the
distance between Zi{1 and Zi. Each function determines the
probability that Zi is in its island state given that Zi{1 is in the given
islandstate,thataCGisobservedatZi andthat noCGsare observed
for the distance of di. The parameters 0.00031434, 0.0257, 0.10178,
0.01298 and 0.013, respectively determine the probability of entering
an island, of leaving an island, the probability of the sequence ‘CG’
occurring in an island, and out of one, and the initial probability that
a site of the genome is in an island. These parameters were set using
maximum likelihood estimates, calculated using chromosomes 21
and 22 of the human genome (Text S1). In cases where the successor
variable of a pair of adjacent variables is of type Y, the methylation
value of the state is considered. MetMap’s current version assumes
independence of the neighboring sites’ methylation values, given the
island values.
Parameters 0.2269, 0.05 and 0.7231 determine the probabilities
of having an M, P or U methylation value, given an unmethylated
island status (I). Parameters 0.8087, 0.05 and 0.1413 determine
these probabilities, given an outside of unmethylated island status
(N) (Text S1). The transition function to any state of Y is
determined as the product of the transition probability considering
only island values (as specified above) and the probability of
observing the methylation value of the state at hand, given its
island value. The third type of probability distribution in MetMap
annotates the dependencies between the Y and V variables. Each
V variable is dependent on the methylation values of the Y
variables on the fragment it represents (Figure 3.b). Therefore, a
dependency function is denoted for each Vi variable as
p(viDConfi), where vi [f0,::,9g is a state of Vi and Confi is some
configuration (assignment) of the values fM, P, Ug of all the
restriction sites on fragment i. We limit the number of Y variables
in the interior of such structures to at most 3 (by random choice
from the interior variables), and unite methylation configurations
that are equivalent with respect to the probability function,
resulting in lookup tables of size at most 5610. The parameters in
the lookup table were determined using a linear program that
takes into consideration the internal constraints of the probability
distributions (Text S1). Artificial restriction of the number of
interior variables is not common because the maximum fragment
length imposed by the size selection is relatively short.
MetMap infers the posterior probabilities of its hidden states by
building the junction-tree graph and using belief propagation [27].
The structure of the graph makes this computation tractable and
efficient: the running time for the inference procedure is less than
an hour for large chromosomes on a small sized cluster.
MetMap generates two output files. One holds for each HpaII
site in the scope of the experiment a MetMap score, indicating the
inferred frequency of alleles in the MethylSeq sample that are
unmethylated at that site. The second file holds the coordinates
and scores of the annotated SUMIs.
Generating cmax
To generate a value for cmax, MetMap builds a histogram of the
read count intensities for the subset of fragments of length 50–
80bp, which do not hold internal restriction sites, and are located
inside UCSC CpG islands. The fragments participating in the
histogram contain a greatly reduced amount of bias (due to the
lack of restriction sites in their interior) and are assumed to be
mostly unmethylated (as they are in CpG islands). Under the
assumption that the distribution of the histogram is close to
Poisson, because the sequencing of fragments is equivalent to
sampling them from the digest, we assume the variance is equal to
the mean, and take cmax to be the value two standard deviations
away from the mean of the distribution. The procedure described
is carried out to avoid setting cmax in a way which is harshly
influenced by PCR amplification bias, a phenomenon that causes
some sites of the genome to receive extremely high counts,
regardless of the extent to which they are methylated.
CG Sites in the Scope of the MethylSeq Experiment
MetMap outputs methylation scores only for the HpaII sites
(CCGGs) that are in the scope of the MethylSeq experiment. A
HpaII site is in the scope of an experiment if and only if it lies on
some fragment that has HpaII sites at its ends, and is of length l
such that lminƒlƒlmax, where lmin and lmax are the minimal and
maximal fragment lengths for a specific MethylSeq experiment.
MetMap’s graphical model identifies these sites; they are all HpaII
site variables (Y variables) that have an edge to some fragment
variable (V variable). Importantly, this condition does not require
a site to be at an end of a fragment that satisfies the length
requirements; a site may be in the interior of such a fragment.
Annotating SUMIs
The SUMI regions annotated by MetMap are the union of two
sets of regions. The first set consists of those continuous regions in
which each Z or Y variable of the MetMap model (CG sites)
received a probability of being in an unmethylated island (p(I))
that is larger than 0.1, and in which the MethylSeq data directly
supports the presence of at least two fragments. This set will
include regions with relatively weak direct experimental evidence
but with strong sequence evidence for being unmethylated. The
second set is generated by setting a 600bp interval around each
HpaII site that had a p(I) value smaller than 0.1 and a p(U) value
higher than the prior probability of being unmethylated outside of
an unmethylated-island (0.1663). All overlapping windows are
concatenated and the regions taken are those in which at least
30% of the HpaII sites had a p(U) larger than the prior-set
threshold (0.1663), and in which the MethylSeq data directly
supports the presence of at least two fragments. This set includes
regions with weaker sequence support for unmethylation, but with
extensive evidence that they are unmethylated. Each SUMI
receives a score, specifying the mean of the MetMap scores at all of
the sites within the SUMI.
The SUMI lists for the four human neutrophil samples can be
found at:
http://www.cs.berkeley.edu/meromit/SUMIs_Human_Neutrophil/
Validation with Bisulfite Sequencing
DNA was treated with the MethylEasy bisulfite conversion kit
(Human Genetic Signatures), PCR-amplified with locus-specific
primers that recognized human target sequences, and sequenced
using standard Sanger chemistry. Since all epialleles from a single
specimen were sequenced in bulk in the same mixture, we
estimated the ratio of unmethylated/methylated alleles at each CG
in the sequence by examining the relative heights of the ‘C’ and
‘T’ traces in the sequencing output. Each CG site received a score
from the set (0,0.25,0.5,0.75,1), based on the relative C/T peak
height [32]. A score of 1 indicates the site is fully unmethylated,
meaning that only the ‘T’ trace was observed at the C position of a
given CG, while a score of 0 indicates the site is fully methylated,
meaning that only the ‘C’ trace was observed at the C position of a
given CG.
MetMap Enables Genome-Scale Methyltyping
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We tested the extent to which our results may be affected by the
representation of the bisulfite scores on a discrete five-point scale,
since the true proportion of alleles that are unmethylated is a close
to continuous measure. Each data point was assigned an ‘adjusted’
bisulfite score, within a tolerance window specified by the true
bisulfite value of that data point. The ‘feasible ranges’ allowed for
the ‘adjusted’ bisulfite scores were as follows: (0,0.15) for a 0
bisulfite score, (0.15,0.35) for a 0.25 score, (0.35,0.65) for a 0.5
score, (0.65,0.85) of a 0.75 score and (0.85,1) for a 1 score. For
example, for a site with bisulfite score 0.25, read count score 0 and
MetMap prediction 0.4 we would get two pairings (0.15,0) for
(adjusted-bisulfite, read count score), and (0.35,0.4) for (adjusted-
bisulfite, MetMap score). The score ranges were based on an
assumption that assignments of ‘‘0.5’’ scores were the least precise.
The adjustment of the bisulfite score to the read counts was done
by generating a normalized read count value, in the 0–1 range,
using the same ‘‘capping’’ value as MetMap.
Open Chromatin ENCODE Files
One file of open chromatin was compiled from:
ftp://hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC/
wgEncodeChromatinMap/
using the files: wgEncodeUncFAIREseqPeaksH1hesc.narrowPeak
wgEncodeUncFAIREseqPeaksNhek.narrowPeak
wgEncodeUncFAIREseqPeaksGm12878V2.narrowPeak
wgEncodeUncFAIREseqPeaksHuvec.narrowPeak
wgEncodeUncFAIREseqPeaksPanislets.narrowPeak
Supporting Information
Figure S1 Validation of MetMap predictions by site-specific
bisulfite sequencing.
Found at: doi:10.1371/journal.pcbi.1000888.s001 (0.45 MB PDF)
Table S1 Read counts of the different samples.
Found at: doi:10.1371/journal.pcbi.1000888.s002 (0.09 MB PDF)
Text S1 Supporting material on MetMap’s algorithms and
parameters.
Found at: doi:10.1371/journal.pcbi.1000888.s003 (0.24 MB PDF)
Text S2 Supporting information on MetMap’s performance and
sensitivity.
Found at: doi:10.1371/journal.pcbi.1000888.s004 (3.48 MB PDF)
Text S3 Supporting information for Figure 4.
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